A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs MK-1697 (Primary)
- Indications Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 18 Mar 2019 Planned End Date changed from 16 Aug 2021 to 11 Sep 2022.
- 18 Mar 2019 Planned primary completion date changed from 16 Aug 2021 to 11 Sep 2022.
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.